Vertex Pharmaceuticals Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Vertex Pharmaceuticals (VRTX) reported strong third-quarter results, with total revenue reaching $3.44 billion, a 12% increase driven by its cystic fibrosis franchise and expanding newer product lines. Following these results, the company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion, up from previous estimates. The quarter was marked by significant growth in new therapies, including CASGEVY, which saw 30% sequential revenue growth, and JOURNAVX, which experienced a 40% increase in prescriptions. Despite increased spending related to the Crinetics acquisition and commercial build-outs for renal and acute pain franchises, Vertex maintains a robust cash position of $9.8 billion.
Topics: Acquisition Cystic Fibrosis Financial Guidance Revenue Growth Share Repurchases